Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC).

Curr Oncol Rep · 2026 · PMC13070087 · PMID 41964727

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

While there was no significant difference in the overall response rate ( p = 0.09), erlotinib showed a trend toward better results (54.1% ORR vs. 34.3% for GC).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.